---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000048"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:34:00.544624+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics granted US composition-of-matter patent for certepetide expiring 2040

## Summary
- U.S. Patent No. 12,351,653 covers certepetide's chemical structure and pharmacokinetic properties.
- Patent expires March 2040 with opportunity for patent term extension.
- CEO states strengthened IP estate and long-term market exclusivity for certepetide.
- Patent includes claims for treating solid tumor cancers and methods of manufacture.

## SEC filing metadata
- accession: 0000320017-25-000048
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000048/0000320017-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000048/clbs-20250715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000048
- JSON: https://secwatch.observer/filing/0000320017-25-000048.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.